Immunotherapy for early-stage nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) for people with early-stage nasopharyngeal cancer that is linked to the Epstein-Barr virus. The goal is to see if these drugs can help shrink the tumor and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of nasopharyngeal cancer that is non-keratinizing and linked to the Epstein-Barr virus (EBV).
- Your cancer is at an early stage (T1 or T2, with lymph node involvement up to N2, and no spread to distant organs).
- You have not had radiation therapy to the head or neck before, and you have not had chemotherapy for this cancer.
- You have normal hearing or only mild hearing loss.
- You are in good overall health (able to do light activities) and have adequate organ function (like kidney, liver, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment approach for people with locally advanced nasopharyngeal cancer using their blood EBV DNA level (a cancer-related virus marker). It may help doctors choose and adjust therapy based on how much of this marker is in your blood after standard treatment.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests whether giving an immunotherapy drug called adebrelimab, based on levels of EBV DNA in the blood, can help people with advanced nasopharyngeal cancer. It is for those who have finished initial chemotherapy and still have signs of the virus or stable disease.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.